MapLight Therapeutics has filed for an initial public offering to support development of novel treatments targeting schizophrenia and Alzheimer's disease. The company’s pipeline focuses on addressing neurological disorders with unmet medical needs. This filing follows recent industry attention on psychiatric and neurodegenerative drug candidates in clinical pipelines.